Search
Now showing items 41-50 of 590
Imaging features of primary sites and metastatic patterns of angiosarcoma.
(2021-12-18)
Angiosarcomas are rare, aggressive soft tissue sarcomas originating from endothelial cells of lymphatic or vascular origin and associated with a poor prognosis. The clinical and imaging features of angiosarcomas are ...
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
The risk-value trade-off: price and brand information impact consumers' intentions to purchase OTC drugs.
(2021-01-25)
<h4>Background</h4>European countries face fiscal pressure regarding the long-term sustainability of their healthcare system due to increasing levels of public health expenditures and mounting demographic pressures. The ...
The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series.
(2021-12-17)
<h4>Background</h4>COVID-19 has had a significant impact on the well-being and job performance of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set ...
Pol theta inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
(AMER ASSOC CANCER RESEARCH, 2021-12-01)
The evolving management of epithelioid sarcoma.
(2021-07-18)
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
(2021-06-22)
In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2- advanced breast cancer. We report data for clinically prognostic ...
Molecular mechanisms of PARP inhibitor sensitivity in primary triple negative breast cancer
(Institute of Cancer Research (University Of London), 2021-08-31)
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harbouring evidence of defective homologous recombination (HR) DNA repair. At present there are no biomarkers available in ...
Circulating tumour DNA in advanced thyroid cancer
(Institute of Cancer Research (University Of London), 2021-02-28)
Conventional biomarkers currently used in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful in other ...
SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study.
(2021-03-02)
Objective To evaluate the performance of new lateral flow immunoassays (LFIAs) suitable for use in a national coronavirus disease 2019 (covid-19) seroprevalence programme (real time assessment of community transmission ...